Skip to main content
Livermore
Livermore
中文EN

Kailera Therapeutics, Inc.

KLRA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0002096997

No open-market purchases or sales by Kailera Therapeutics, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $2.58B in total; Soros Fund Management is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kailera Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kailera Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kailera Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Nicholson NurChief Technology Officer–Sep 9, 20261
Tregoning KathleenSee Remarks–Jul 8, 20261
Renaud Ronald C JRCEO & President38,094Jun 11, 20262
RTW Investments, LP10% Owner10,776,820IndirectApr 22, 20261
Wong Roderick10% Owner10,776,820IndirectApr 22, 20261
Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% Owner2,034,133Apr 22, 20261
Bain Capital Investors LLC10% Owner26,255,581IndirectApr 20, 20261
Bain Capital Fund XIV, L.P.10% Owner26,255,581IndirectApr 20, 20261
Bain Capital XIV General Partner, LLC10% Owner26,255,581IndirectApr 20, 20261
BCPE Perseus Investor GP, LLC10% Owner26,255,581IndirectApr 20, 20261
BCPE Perseus Investor, LP10% Owner26,255,581IndirectApr 20, 20261
Bain Capital Life Sciences Investors, LLC10% Owner22,583,268IndirectApr 20, 20261
Bain Capital Life Sciences IV General Partner, LLC10% Owner22,583,268IndirectApr 20, 20261
Bain Capital Life Sciences Fund IV, L.P.10% Owner22,583,268IndirectApr 20, 20261
BCLS Fund IV Investments, L.P.10% Owner22,583,268IndirectApr 20, 20261
BCLS Fund IV Investments GP, LLC10% Owner22,583,268IndirectApr 20, 20261
Milligan John FDirector–Apr 20, 20261
Mackay MartinDirector–Apr 20, 20261
Koppel AdamDirector, 10% Owner22,583,268IndirectApr 20, 20261
Pagan Douglas W.Chief Financial Officer–Apr 20, 20261
Burgess Paul D.See Remarks–Apr 20, 20261
Cloghessy PaulaChief People Officer–Apr 20, 20261
Kaplan Andrew T.Director, 10% Owner26,255,581IndirectApr 20, 20261
Clyburn FrankDirector–Apr 20, 20261
Hite ChristopherDirector–Apr 20, 20261
Akamine ScottChief Legal Officer–Apr 20, 20261
Coleman Jamie BethChief Commercial Officer–Apr 20, 20261
Wasserman Scott M.Chief Medical Officer–Apr 20, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 22, 2026 (view filing)4:15 PM ETApr 202 daysRTW Investments, LP and 1 other10% OwnerPPurchase+500.0K$16.00+$8.00M+4.9%10.8M after
Apr 20, 2026 (view filing)6:10 PM ETApr 20Same dayBain Capital Investors LLC and 4 others10% OwnerPPurchase+8.40M$16.00+$134.4M+47.0%26.3M afterDuplicate filing
Apr 20, 2026 (view filing)6:01 PM ETApr 20Same dayBain Capital Life Sciences Investors, LLC and 4 others10% OwnerPPurchase+1.56M$16.00+$25.0M+7.4%22.6M afterDuplicate filing
Apr 20, 2026 (view filing)Apr 20Same dayKoppel AdamDirector, 10% OwnerPPurchase+1.56M$16.00+$25.0M+7.4%22.6M after
Apr 20, 2026 (view filing)Apr 20Same dayKaplan Andrew T.Director, 10% OwnerPPurchase+8.40M$16.00+$134.4M+47.0%26.3M after